KRAS and pancreatic neoplasm: To assess the efficacy of TUS-007 in pancreatic cancer, for which the development of an effective molecular targeted drug has thus far been unsuccessful, we assayed apoptosis and antitumor effects on SW1990 human pancreatic cancer cells (homozygous KRAS G12D).